K. Fujiwara

K. Kiura, M. Tabata, H. Ueoka, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.

M. Hatae, J. Kigawa, D. Aoki, 2011, Japanese journal of clinical oncology.

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)

S. Kusumoto, K. Shiraishi, K. Kaira, 2021, Therapeutic advances in medical oncology.

Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer

H. Chung, Soon‐Beom Kang, M. Takeuchi, 2018, British Journal of Cancer.

Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy.

K. Fujiwara, S. Nagao, I. Kohno, 2006, Gynecologic oncology.

Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.

Y. Ohashi, M. Hatae, T. Ohno, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better.

Y. Ohashi, Kenichi Tanaka, Y. Takegawa, 2006, Gynecologic oncology.

Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.

K. Fujiwara, S. Nagao, I. Kohno, 2005, Gynecologic oncology.

A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.

K. Kiura, M. Tabata, M. Tanimoto, 2011, Lung cancer.

Two cases of atypical carcinoid of the thymus.

K. Eguchi, M. Ida, M. Nakata, 2000, Internal medicine.

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

M. Takano, T. Sugiyama, K. Fujiwara, 2020, Journal of gynecologic oncology.

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

M. Kodaira, Y. Fujiwara, K. Yamashita, 2014, Investigational New Drugs.

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane‐resistant/refractory epithelial ovarian, tubal and peritoneal cancers

T. Goto, M. Takano, K. Hasegawa, 2010, The journal of obstetrics and gynaecology research.

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2004, Lung cancer.

Improving cancer outcomes through international collaboration in academic cancer treatment trials.

E. Trimble, B. Vikram, D. Lacombe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.

K. Matsuo, H. Ueoka, K. Tajima, 2007, Asian Pacific journal of cancer prevention : APJCP.

Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.

K. Kiura, M. Tabata, H. Ueoka, 2007, Oncology reports.

Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.

K. Kiura, M. Tabata, H. Ueoka, 2003, Lung cancer.

A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.

K. Kiura, I. Yamadori, K. Kudo, 2011, Japanese journal of clinical oncology.

Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?

K. Kiura, M. Tabata, H. Ueoka, 2005, Anticancer research.

Toxicity manifesting as cosmetic hair alterations during erlotinib treatment

K. Kudo, T. Sato, K. Fujiwara, 2011, Acta oncologica.

Multiple Mucosa-associated Lymphoid Tissue Lymphoma of the Trachea

K. Fujiwara, Chihiro Ando, D. Minami, 2017, Internal medicine.

Mesonephric adenocarcinoma with a sarcomatous component, a notable subtype of cervical carcinosarcoma: a case report and review of the literature

M. Shimizu, M. Yasuda, K. Fujiwara, 2013, Diagnostic Pathology.

Multimodality Treatment for Thymic Carcinoma: Review of 11 Cases at a Single Institute

A. Andou, K. Fujiwara, Hisao Higo, 2013 .

A pilot study of mobile digital colposcopy in Japanese patients with cervical intraepithelial neoplasm

K. Hasegawa, K. Fujiwara, Sho Sato, 2021, Molecular and clinical oncology.

Phase II Study of Combination Chemotherapy With Docetaxel and Carboplatin for Locally Advanced or Recurrent Cervical Cancer

J. Kigawa, N. Terakawa, S. Yamaguchi, 2010, International Journal of Gynecologic Cancer.

Adenocarcinoma of the Uterine Cervix: Why Is it Different?

B. Monk, M. Devouassoux‐Shisheboran, K. Fujiwara, 2014, Current Oncology Reports.

Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry

H. Mukai, Y. Ohashi, M. Ikeda, 2020, Japanese journal of clinical oncology.

Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer

K. Hasegawa, K. Fujiwara, S. Nagao, 2013, Expert opinion on pharmacotherapy.

Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.

K. Fujiwara, S. Nagao, I. Kohno, 2005, Gynecologic oncology.

A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer.

J. Kigawa, N. Terakawa, K. Fujiwara, 2003, Gynecologic oncology.

Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline

E. Kohn, Z. Aziz, S. Temin, 2021, JCO global oncology.

PROGRESS IN THE TREATMENT OF OVARIAN CANCER. LESSONS FROM HOMOLOGOUS. RECOMBINATION DEFICIENCY

J. Ledermann, T. Perren, K. Fujiwara, 2015 .

Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).

B. Monk, I. Vergote, S. Pignata, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma

Jae-Weon Kim, B. Monk, S. Pignata, 2014, International Journal of Gynecologic Cancer.

Subject Index, Volume 42, 1998

G. Nilsson, O. Larsson, M. Tsou, 1998, Acta Cytologica.

Contributor Index, Volume 42, 1998

G. Nilsson, O. Larsson, M. Tsou, 1998, Acta Cytologica.

Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy.

K. Fujiwara, Hisao Higo, Kammei Rai, 2014, Internal medicine.

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

A. Oza, M. Friedlander, N. Colombo, 2022, Gynecologic oncology.

Randomized phase II study of immunomodulator Z-100 in patients with stage IIIB cervical cancer with radiation therapy.

Y. Ohashi, Y. Takegawa, H. Niibe, 2006, Japanese journal of clinical oncology.

Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry)

H. Mukai, Y. Ohashi, M. Ikeda, 2018, BMJ Open.

First-Line Therapy in Ovarian Cancer Trials

H. Kitchener, J. McAlpine, L. Rubinstein, 2011, International Journal of Gynecologic Cancer.

Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion

S. Toyooka, K. Matsuo, H. Ueoka, 2007, International journal of cancer.

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

B. Monk, A. Tinker, A. Oza, 2021, The Lancet. Oncology.

Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases.

K. Fujiwara, S. Suzuki, H. Yamauchi, 1998, Gynecologic oncology.

PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy

Mitsuaki Suzuki, J. Kigawa, H. Itamochi, 2002, International journal of cancer.

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

H. Gabra, A. Sood, N. Matsumura, 2015, European journal of cancer.

Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial

B. Monk, A. Oza, J. Ledermann, 2020 .

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

F. Marmé, I. Vergote, S. Pignata, 2019, The New England journal of medicine.

Squamous cell carcinoma of the uterine cervix in association with stage 0 chronic lymphocytic leukemia/small lymphocytic lymphoma.

H. Sasano, Y. Mikami, K. Fujiwara, 2004, Gynecologic oncology.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

K. Yonemori, S. Pignata, I. Ray-Coquard, 2022, The New England journal of medicine.

Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment

H. Matsuura, K. Fujiwara, D. Minami, 2020, Case Reports in Oncology.

Clinical Characteristics of Severe Refractory Asthma Associated with the Effectiveness of Bronchial Thermoplasty.

K. Fujiwara, D. Minami, Toshio Sato, 2019, Acta medica Okayama.

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

K. Fujiwara, D. Minami, T. Shibayama, 2018, Respirology case reports.

Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin

K. Fujiwara, H. Ueki, A. Hatamochi, 1984, Archives of Dermatological Research.

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

K. Kiura, M. Tabata, K. Hotta, 2019, Japanese journal of clinical oncology.

Can carboplatin replace cisplatin for intraperitoneal use?

K. Fujiwara, 2008, International Journal of Gynecologic Cancer.

Aberrant promoter hypermethylation in serum DNA from patients with silicosis.

K. Kiura, M. Tabata, H. Ueoka, 2008, Carcinogenesis.

Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer

H. Matsuura, S. Mitsumune, K. Kudo, 2021, Case Reports in Oncology.

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

E. Kohn, V. Gebski, A. Reuss, 2022, The Lancet. Oncology.

A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer

Mitsuaki Suzuki, M. Shimada, K. Hasegawa, 2020, British Journal of Cancer.

Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma: A Feasibility Study

T. Goto, K. Hasegawa, K. Fujiwara, 2012, International Journal of Gynecologic Cancer.

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.

M. Morgan, S. Waggoner, S. Rubin, 2011, Gynecologic oncology.

A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.

Mitsuaki Suzuki, M. Takeuchi, H. Yoshikawa, 2011, Japanese journal of clinical oncology.

Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer: A Sankai Gynecology Cancer Study Group Study

J. Kigawa, Y. Miyagi, K. Fujiwara, 2009, International Journal of Gynecologic Cancer.

Erratum to “First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up”: [Gynecol. Oncol. 90 (2003) 637–643]☆

N. Sakuragi, K. Fujiwara, H. Sawai, 2003 .

Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.

M. Morgan, R. Coleman, M. Markman, 2005, Gynecologic oncology.

Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube

K. Fujiwara, S. Suzuki, I. Kohno, 2004, International Journal of Gynecologic Cancer.

Targeted therapy in gynecologic cancers: Ready for prime time?

M. Seoud, E. Å. Lundqvist, K. Fujiwara, 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.

K. Hasegawa, K. Fujiwara, S. Nagao, 2014, Japanese journal of clinical oncology.

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

H. Kuramoto, T. Jobo, D. Aoki, 2005, British Journal of Cancer.

Effect of Lymphovascular Space Invasion on Survival of Stage I Epithelial Ovarian Cancer

Y. Shiki, A. Sood, T. Enomoto, 2014, Obstetrics and gynecology.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

P. Sabbatini, R. Coleman, T. Herzog, 2015 .

B. Monk, R. Coleman, T. Herzog, 2014 .

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Richard G. Moore, E. Kohn, D. Cella, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy

K. Hasegawa, K. Fujiwara, S. Nagao, 2019, Cancer.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

B. Monk, B. Karlan, A. Oza, 2014 .

Clinical aspect of Doxil

K. Fujiwara, 2009 .

Splenectomy during secondary cytoreductive surgery for epithelial ovarian cancer.

K. Fujiwara, S. Nagao, J. Hanprasertpong, 2010, Asian Pacific journal of cancer prevention : APJCP.

Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?

K. Hasegawa, K. Fujiwara, A. Kurosaki, 2013, Current Oncology Reports.

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

[The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].

K. Fujiwara, S. Sawada, H. Yamauchi, 1992, Gan to kagaku ryoho. Cancer & chemotherapy.

Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma

E. Noguchi, A. Shimomura, K. Yonemori, 2020, Oncology.

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study

K. Hasegawa, M. Yasuda, K. Fujiwara, 2016, Journal of gynecologic oncology.

Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213.

P. Sabbatini, R. Coleman, T. Herzog, 2016 .

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

R. Burger, M. Birrer, A. Secord, 2016 .

Subcutaneous transposition of the ovary following hysterectomy

K. Fujiwara, H. Yamauchi, T. Yoshida, 1997, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

B. Monk, M. Morgan, D. Provencher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation-induced vesico-vaginal fistula successfully repaired using a gracilis myocutaneous flap

I. Koshima, T. Moriguchi, K. Fujiwara, 2000, International Journal of Clinical Oncology.

Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy.

H. Shigematsu, A. Andou, I. Yamadori, 2012, Internal medicine.

Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report

S. Mitsumune, K. Kudo, K. Fujiwara, 2021, Case Reports in Oncology.

Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy

J. Kigawa, H. Itamochi, N. Terakawa, 2002, International Journal of Gynecologic Cancer.

Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2005, Internal medicine.

Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.

H. Aburatani, K. Oda, Y. Osuga, 2019, Gynecologic oncology.

A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy.

K. Eguchi, S. Umemura, N. Seki, 2002, Japanese journal of clinical oncology.

The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin

K. Hasegawa, K. Fujiwara, S. Nagao, 2015, International Journal of Gynecologic Cancer.

Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele.

K. Kiura, M. Tanimoto, T. Yoshino, 2001, Biochemical and biophysical research communications.

Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826

A. Okamoto, M. Yunokawa, K. Yonemori, 2022, Cancer science.

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775

M. Yunokawa, K. Yonemori, K. Ushijima, 2022, Cancer science.

Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan

H. Matsuura, S. Mitsumune, K. Kudo, 2020, Internal medicine.

Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients

K. Fujiwara, S. Suzuki, I. Kohno, 2002, International Journal of Clinical Oncology.

Rapidly Progressive Multiple Cavity Formation in Necrotizing Pneumonia Caused by Community-acquired Methicillin-resistant Staphylococcus aureus Positive for the Panton-Valentine Leucocidin Gene

M. Nagao, K. Fujiwara, Takashi Saito, 2018, Internal medicine.

Title Rapidly Progressive Multiple Cavity Formation in Necrotizing Pneumonia Caused by Community-acquired Methicillin-resistant Staphylococcus aureus Positive for the Panton

M. Nagao, K. Fujiwara, Takashi Saito, 2019 .

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.

M. Birrer, K. Yonemori, A. Secord, 2022, Gynecologic oncology.

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

E. Miyaoka, A. Gemma, M. Seike, 2022, JTO clinical and research reports.

Rapidly progressing multiple cardiac rhabdomyosarcoma

I. Yamadori, K. Miyaji, K. Fujiwara, 2010, Journal of echocardiography.

Photosensitivity reaction induced by erlotinib

K. Fujiwara, Hisao Higo, Toshio Sato, 2012, International Cancer Conference Journal.

Surgical and systemic management of endometrial cancer: an international survey

S. Kehoe, I. Vergote, D. Miller, 2015, Archives of Gynecology and Obstetrics.

Comparing the Clinical Performance of the New 19-G ViziShot FLEX and 21- or 22-G ViziShot 2 Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Needles

K. Fujiwara, D. Minami, T. Shibayama, 2018, Internal medicine.

Therapeutic effect of hyperthermia combined with chemotherapy on vulvar and vaginal carcinoma.

K. Fujiwara, K. Sekiba, I. Kohno, 1987, Acta medica Okayama.

Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy

J. Kigawa, H. Itamochi, N. Terakawa, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Clinical implications of metastases to the ovary.

K. Fujiwara, S. Sawada, I. Kohno, 1995, Gynecologic oncology.

Update on nonserous ovarian cancer trials.

K. Hasegawa, K. Fujiwara, H. Yoshida, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer

K. Fujiwara, D. Minami, T. Shibayama, 2019, Internal medicine.

Principles and practice of intraperitoneal chemotherapy for ovarian cancer

M. Morgan, D. Armstrong, M. Markman, 2006, International Journal of Gynecologic Cancer.

[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].

H. Taniguchi, K. Fujiwara, T. Kiba, 2014, Gan to kagaku ryoho. Cancer & chemotherapy.

Supernumerary Ovary Found by Ultrasonogram and FSH Measurement after an Extensive Operation for a Yolk Sac Tumor of the Ovary

K. Fujiwara, I. Kohno, Takako Shirotani, 1999, Gynecologic and Obstetric Investigation.

Adenoid basal carcinoma of the cervix uteri: A case report

T. Manabe, M. Shimizu, Y. Mikami, 1997, Pathology international.

Pregnancy in a woman with a Y chromosome after removal of an ovarian dysgerminoma.

Y. Mikami, K. Fujiwara, H. Yamauchi, 2000, Gynecologic oncology.

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways

M. Birrer, I. Ray-Coquard, A. Oaknin, 2022, Frontiers in Oncology.

Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’

T. Manabe, H. Sasano, N. Yaegashi, 2004, Modern Pathology.

Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma

T. Noda, S. Mori, N. Matsumura, 2019, Nature Communications.

Basement Membrane Material and Tigroid Background in a Fine Needle Aspirate of Clear Cell Adenocarcinoma of the Cervix

T. Manabe, M. Hirokawa, M. Shimizu, 2000, Acta Cytologica.

Nuclear findings of ovarian surface epithelial tumors

T. Manabe, M. Hirokawa, M. Shimizu, 2000, Diagnostic cytopathology.

Diagnostic Value of Hair Shafts and Squamous Cells in Peritoneal Washing Cytology

T. Manabe, M. Hirokawa, K. Fujiwara, 2000, Acta Cytologica.

Joint IARC/NCI International Cancer Seminar Series Report: Expert consensus on future directions for ovarian carcinoma research.

Kathleen R. Cho, Jae-Weon Kim, S. Chanock, 2021, Carcinogenesis.

Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.

Keitaro Matsuo, Masahiro Tabata, K. Matsuo, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer

Yusuke Nakamura, T. Miyamoto, Jae-Hyun Park, 2016, Clinical Cancer Research.

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations

K. Hasegawa, Y. Ikeda, K. Fujiwara, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Principles of chemotherapy.

M. Seoud, E. Å. Lundqvist, K. Fujiwara, 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53

H. Aburatani, Tomohiko Fukuda, K. Oda, 2016, Oncotarget.

Immunogenomic landscape of gynecologic carcinosarcoma.

T. Noda, S. Mori, N. Matsumura, 2020, Gynecologic oncology.

Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma

H. Aburatani, K. Oda, K. Hasegawa, 2020, Journal for immunotherapy of cancer.

Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy

K. Hasegawa, H. Seki, M. Yasuda, 2017, Molecular Diagnosis & Therapy.

p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer

H. Tsuda, T. Goto, M. Takano, 2009, International journal of cancer.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

B. Monk, B. Karlan, A. Oza, 2014, The Lancet. Oncology.

A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance.

I. Vergote, S. Pignata, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial

K. Yonemori, I. Ray-Coquard, Takashi Matsumoto, 2021, Journal of gynecologic oncology.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Val Gebski, Philipp Harter, Tomasz Huzarski, 2017, The Lancet. Oncology.

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

T. Shimoi, M. Yunokawa, K. Yonemori, 2017, Cancer science.

Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression

K. Hasegawa, M. Yasuda, K. Fujiwara, 2017, Oncology letters.

Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression

K. Hasegawa, D. O'Shannessy, M. Yasuda, 2016, International journal of cancer.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Rare Uterine Malignant Tumors

I. Ray-Coquard, F. Amant, M. Friedlander, 2019, Management of Endometrial Cancer.

Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype

T. Manabe, J. Melamed, Y. Mikami, 2001, Histopathology.

Florid endocervical glandular hyperplasia with intestinal and pyloric gland metaplasia: worrisome benign mimic of "adenoma malignum".

T. Manabe, Y. Mikami, K. Fujiwara, 1999, Gynecologic oncology.

Endocervical adenomyoma

T. Manabe, Y. Mikami, K. Fujiwara, 2008 .

Endocervical adenomyoma. A case report with histochemical and immunohistochemical studies.

T. Manabe, Y. Mikami, K. Fujiwara, 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Florid endocervical glandular hyperplasia with pyloric gland metaplasia: a radiologic pitfall.

Y. Mikami, K. Fujiwara, E. Yoden, 2001, Journal of computer assisted tomography.

Irinotecan hydrochloride for the treatment of recurrent and refractory non‐Hodgkin lymphoma

T. Saotome, K. Fujiwara, Yoshinori Ito, 2002, Cancer.

Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial

K. Kiura, M. Tabata, H. Ueoka, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.

Jae-Weon Kim, V. Gebski, A. Oza, 2020, European journal of cancer.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix

Jae-Weon Kim, R. Glasspool, M. Friedlander, 2014, International Journal of Gynecologic Cancer.

Contemporary management of endometrial cancer

T. Herzog, J. Sehouli, K. Fujiwara, 2012, The Lancet.

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.

A. Okamoto, S. Pignata, Kiyoko Kato, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of temsirolimus in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary.

M. Yunokawa, D. Gershenson, H. Nomura, 2016 .

Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas

H. Aburatani, M. Fukayama, D. Maeda, 2015, PloS one.

Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma

K. Hasegawa, K. Fujiwara, Sho Sato, 2022, BMC Cancer.

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.

K. Kiura, M. Tanimoto, K. Tsubouchi, 2012, Lung cancer.

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

I. Vergote, S. Pignata, I. Ray-Coquard, 2020, JAMA oncology.

Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study.

A. Okamoto, S. Pignata, Kiyoko Kato, 2014 .

Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO).

I. Vergote, W. Lichtenegger, D. Miller, 2013 .

Critical appraisal of bevacizumab in the treatment of ovarian cancer

K. Fujiwara, H. Yoshida, A. Yabuno, 2015, Drug design, development and therapy.

Papillary squamous cell carcinoma of the uterine cervix: diagnostic pitfalls

T. Manabe, M. Hirokawa, M. Shimizu, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)

I. Konishi, D. Aoki, J. Hamanishi, 2020 .

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Danielle M. Enserro, Jae-Weon Kim, P. Sabbatini, 2019, The New England journal of medicine.

Evaluation of Endometrial Cytology: Cytohistological Correlations in 1,441 Cancer Patients

Yoshifumi Takahashi, M. Takano, K. Fujiwara, 2014, Oncology.

MR imaging of polypoid endometriosis of the ovary.

M. Yasuda, K. Fujiwara, E. Kozawa, 2012, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

Oxyphilic cell variant of endometrioid adenocarcinoma

T. Manabe, M. Hirokawa, M. Shimizu, 1998, Pathology international.

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

R. Burger, K. Owzar, M. Birrer, 2020, Clinical Cancer Research.

Adenocarcinoma in Situ of the Fallopian Tube

T. Manabe, M. Hirokawa, M. Shimizu, 1998, Acta Cytologica.

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100

K. Ushijima, K. Hasegawa, D. Aoki, 2020, Cancer science.

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

B. Monk, A. Oza, F. Marmé, 2021, International Journal of Gynecological Cancer.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

B. Monk, A. Oza, J. Ledermann, 2021, The Lancet. Oncology.

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

B. Monk, A. Tinker, A. Oza, 2019, Gynecologic Oncology.

Is the Adjustment of Serum Creatinine Level from < 0.6 mg/dL to 0.6 mg/dL Justified in Estimating Carboplatin Clearance Calculated by the Jelliffe Formula?

T. Goto, K. Hasegawa, K. Fujiwara, 2009 .

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.

D. Mutch, T. Herzog, C. Tian, 2008, Gynecologic oncology.

Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings.

T. Sakurai, K. Fujiwara, E. Kozawa, 2010, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix

D. Provencher, J. Ledermann, I. Treilleux, 2014, International Journal of Gynecologic Cancer.

SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study

P. Hillemanns, R. Zweemer, E. Hudson, 2019, International Journal of Gynecological Cancer.

FIGO Committee for the Ethical Aspects of Human Reproduction and Women’s Health

D. Luthy, T. Chung, E. Steegers, 1999, Gynecologic and Obstetric Investigation.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.

B. Monk, R. Wenham, H. Gabra, 2023, Gynecologic oncology.

Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.

K. Kiura, M. Tabata, K. Hotta, 2020, Japanese journal of clinical oncology.

Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence

M. Shimada, K. Matsuo, M. Mikami, 2020, Current Oncology Reports.

Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers

Michiko Takahashi, N. Kino, T. Goto, 2009, Oncology.

Clear-cell carcinoma of the ovary.

K. Fujiwara, D. Shintani, T. Nishikawa, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clear Cell Carcinoma

M. Takano, S. Takakura, K. Fujiwara, 2017 .

Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas

H. Aburatani, M. Fukayama, D. Maeda, 2015, PloS one.

T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.

Yusuke Nakamura, T. Miyamoto, Jae-Hyun Park, 2016, Clinical cancer research : an official journal of the American Association for Cancer Research.

A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

K. Yonemori, S. Pignata, I. Ray-Coquard, 2021, Gynecologic Oncology.

527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

F. Marmé, R. Kristeleit, A. Oaknin, 2022, Annals of Oncology.

LBA31 Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial

K. Takehara, K. Fujiwara, S. Nishio, 2022, Annals of Oncology.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

B. Monk, H. Mackay, D. Miller, 2021, Annals of Oncology.

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

A. Okamoto, H. Watari, N. Sakuragi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-world database analysis of the characteristics and treatment patterns of patients with endometrial cancer in Japan

K. Aoshima, K. Fujiwara, Keishi Akada, 2021, Current medical research and opinion.

Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?

H. Yoshikawa, M. Takano, T. Minegishi, 2013, British Journal of Cancer.

Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer.

K. Fujiwara, H. Yoshida, Naoyuki Kawashima, 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer.

K. Fujiwara, Y. Imai, H. Yoshida, 2016, Molecular and clinical oncology.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

K. Kiura, M. Tabata, H. Ueoka, 2014, European journal of cancer.

Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.

B. Monk, J. Graham, C. Clarke, 2015, Gynecologic oncology.

High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo

Yusuke Nakamura, T. Miyamoto, K. Hasegawa, 2020, Journal of gynecologic oncology.

Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer

Yusuke Nakamura, K. Hasegawa, T. Tsunoda, 2018, Journal of immunotherapy.

Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer

Yusuke Nakamura, S. Miyano, R. Yamaguchi, 2017, Oncology reports.

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

K. Kiura, M. Tabata, H. Ueoka, 2006, Cancer Chemotherapy and Pharmacology.

Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.

E. Miyagi, K. Hasegawa, K. Kakimi, 2018, Oncology letters.

Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer

K. Hasegawa, K. Kakimi, H. Matsushita, 2022, BMC Cancer.

Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer

K. Hasegawa, K. Kakimi, H. Matsushita, 2022, BMC cancer.

A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.

Craig B. Davis, A. Oza, M. Birrer, 2016, Gynecologic oncology.

Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.

I. Hyodo, S. Takashima, Y. Shimada, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacokinetic S tudy o f a N ew T axoid, R PR 109881A, G iven a s a 1 -Hour I ntravenous I nfusion i n Patients W ith A dvanced S olid T umors

I. Hyodo, S. Takashima, Y. Shimada, 2000 .

[Pleomorphic carcinoma of the lung with uncommon initial manifestation of intestinal perforation].

I. Yamadori, K. Fujiwara, Y. Ueda, 2009, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

Feasibility and response to nedaplatin monotherapy in older patients with ovarian cancer

K. Fujiwara, H. Yoshida, D. Shintani, 2017, Archives of Gynecology and Obstetrics.

The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG

A. Okamoto, T. Enomoto, N. Yaegashi, 2020, Journal of gynecologic oncology.

Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix

J. Kigawa, M. Shimada, N. Takeshima, 2016, International Journal of Clinical Oncology.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

R. Burger, S. Rubin, R. Bristow, 2018, Gynecologic oncology.

Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells

K. Fujiwara, H. Tanaka, I. Kohno, 2003, International Journal of Gynecologic Cancer.

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

Mitsuaki Suzuki, K. Ushijima, J. Kigawa, 2019, International Journal of Clinical Oncology.

A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Danielle M. Enserro, A. Secord, P. Sabbatini, 2018 .

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.

B. Monk, S. Dychter, G. Devgan, 2018, Future oncology.

Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition

Tadao Tanaka, N. Sakuragi, K. Hasegawa, 2010, International Journal of Clinical Oncology.

A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102

K. Kiura, M. Tabata, H. Ueoka, 2016, Cancer Chemotherapy and Pharmacology.

Unusual MR findings in ovarian leiomyoma.

M. Yasuda, K. Fujiwara, E. Kozawa, 2013, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

Obesity is a predictive biomarker of poor benefit from single-agent bevacizumab therapy in recurrent ovarian cancer patients.

K. Fujiwara, H. Yoshida, D. Shintani, 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Primary serous adenocarcinoma of the retroperitoneum with a response to platinum-based chemotherapy: a case report.

M. Hirokawa, K. Fujiwara, S. Suzuki, 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2004, Lung cancer.

S. Pignata, I. Ray-Coquard, N. Colombo, 2021, Journal of Clinical Oncology.

A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.

S. Pignata, C. Aghajanian, R. Penson, 2019, Journal of Clinical Oncology.

Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.

I. Soubeyran, I. Vergote, N. Sevenet, 2020, Journal of the National Cancer Institute.

Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai

Yasunari Miyagi, Ichiro Kohno, Eriko Aotani, 2005, Gynecologic oncology.

The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.

K. Kiura, M. Tabata, K. Hotta, 2018 .

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study

K. Yonemori, J. Buchbjerg, Y. Hirashima, 2022, Cancer science.

Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity.

K. Eguchi, S. Takashima, M. Ida, 2000, International journal of radiation oncology, biology, physics.

Bilateral Testicular Metastases from Lung Adenocarcinoma Showing an Objective Response to Nivolumab: A Case Report and Review of the Literature

K. Fujiwara, D. Minami, T. Shibayama, 2019, Internal medicine.

Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy

K. Fujiwara, E. Yoden, S. Suzuki, 2002, International Journal of Gynecologic Cancer.

Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer

H. Chung, M. Takeuchi, Byoung-Gie Kim, 2018, British Journal of Cancer.

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

V. Gebski, M. Friedlander, B. Ataseven, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

S. Pignata, I. Ray-Coquard, N. Colombo, 2023, European Journal of Cancer.

Development of a Japanese Scale that Evaluates the Level of Nursing Support Provided to Patients for Decision-Making in Cancer Clinical Trials.

K. Fujiwara, H. Nakahama, N. Fujiwara, 2023, Journal of cancer education : the official journal of the American Association for Cancer Education.

Corrigendum to: Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry

H. Mukai, Y. Ohashi, M. Ikeda, 2020, Japanese journal of clinical oncology.

879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer

A. Okamoto, M. Birrer, I. Ray-Coquard, 2020 .

Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.

A. Sood, N. Matsumura, T. Enomoto, 2015, Gynecologic oncology.

Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

K. Kiura, M. Tabata, H. Ueoka, 2004, Cancer Chemotherapy and Pharmacology.

Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma

K. Kiura, M. Tabata, H. Ueoka, 2005, Journal of Cancer Research and Clinical Oncology.

Mitsuaki Suzuki, T. Kanuma, Y. Takei, 2021, The journal of obstetrics and gynaecology research.

Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.

A. Oza, J. McAlpine, S. Lheureux, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study

Y. Takei, K. Fujiwara, S. Nagao, 2023, International Journal of Clinical Oncology.

Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.

Wong Wai Loong, A. Okamoto, K. Hasegawa, 2023, NEJM evidence.

Determination of the activated form of the progesterone receptor (PR) in endometrial cancer (EC).

B. Monk, C. Clarke, J. Bosq, 2013 .

JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.

B. Monk, J. Ledermann, M. Birrer, 2019, Journal of Clinical Oncology.

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer.

K. Fujiwara, H. Yoshida, 2023, Cancer medicine.

Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer

K. Yonemori, S. Pignata, I. Ray-Coquard, 2022, Obstetrical & Gynecological Survey.

Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer

K. Fujiwara, H. Yoshida, D. Shintani, 2020, In Vivo.

Bronchoscopic diagnosis of peripheral pulmonary lung cancer employing sedation with fentanyl and midazolam.

K. Fujiwara, Chihiro Ando, D. Minami, 2017, Respiratory investigation.

Subclinical thiamine deficiency identified by preoperative evaluation in an ovarian cancer patient: Diagnosis and the need for preoperative thiamine measurement

T. Akechi, K. Hasegawa, K. Fujiwara, 2018, Palliative and Supportive Care.

PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

I. Vergote, S. Pignata, I. Ray-Coquard, 2016 .

Association between financial toxicity and health-related quality of life of patients with gynecologic cancer

K. Fujiwara, K. Honda, A. Igarashi, 2023, International Journal of Clinical Oncology.

Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group.

Y. Ohashi, S. Ogita, M. Yakushiji, 1999, Anticancer research.

COX‐2, prostanoids and colon cancer

A. Kato, S. Ota, H. Bamba, 2002 .

2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, Ovarian cancer.

Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

B. Monk, A. Oza, F. Marmé, 2019, Clinical Trials.

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, medRxiv.

Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer

T. Goto, K. Shimoya, K. Fujiwara, 2007, International Journal of Gynecologic Cancer.

Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.

K. Kiura, M. Tabata, K. Hotta, 2023, Respiratory investigation.

The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients

K. Oda, K. Hasegawa, Y. Ikeda, 2015, Oncology Research and Treatment.

Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma

T. Tan, R. Huang, K. Hasegawa, 2020, Scientific Reports.

Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemo

P. Sabbatini, Byoung-Gie Kim, R. Coleman, 2015 .

ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

S. Lheureux, P. Zola, J. Sehouli, 2020, Gynecologic Oncology.

[5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].

K. Inoue, K. Fujiwara, I. Kono, 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.

Danielle M. Enserro, B. Monk, R. Burger, 2021, Gynecologic oncology.

Effect of the exposure dose of etoposide on the cell growth and cell kinetics of human ovarian cancer cells

K. Fujiwara, I. Kohno, Y. Ohishi, 1996, Cancer Chemotherapy and Pharmacology.

Significant increases in serum CA125 and CA19-9 following torsion from an adenofibroma of the ovary: a case report.

Y. Mikami, K. Fujiwara, J. Hiratsuka, 1994, Japanese journal of clinical oncology.

More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance

K. Kiura, K. Hotta, T. Tamura, 2022, Journal of Cancer Research and Clinical Oncology.

Pharmacokinetics of a New Fentanyl Tape with a Novel Delivery System of Transdermal Matrix Patches in Patients with Cancer Pain

S. Saito, K. Fujiwara, K. Shimada, 2013, Oncology.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

B. Monk, C. Schade-Brittinger, R. Kimmig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

V. Gebski, A. Oza, J. Ledermann, 2017, The Lancet. Oncology.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.

N. Sakuragi, K. Fujiwara, H. Sawai, 2003, Gynecologic oncology.

Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression

M. Yasuda, K. Fujiwara, Tomomi Kato, 2017, Oncology letters.

[I. Clinical Development and Prospect of Chemotherapy for Uterine Carcinosarcoma].

K. Yonemori, Y. Fujiwara, K. Fujiwara, 2018, Gan to kagaku ryoho. Cancer & chemotherapy.

2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection

I. Vergote, S. Pignata, I. Treilleux, 2022, Ovarian cancer.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

K. Kiura, M. Tabata, H. Ueoka, 2014, European journal of cancer.

The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin

Yasumasa Tanaka, Ichiro Kohno, K. Fujiwara, 2001, Cancer Chemotherapy and Pharmacology.

Use of IP chemotherapy in ovarian cancer: the critical questions.

E. Trimble, J. Abrams, C. Marth, 2011, Oncology.

ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer

R. Wenham, S. Lheureux, P. Zola, 2019, Annals of Oncology.

Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer

K. Fujiwara, D. Minami, Toshio Sato, 2018, Case Reports in Oncology.